Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217081 | 0.97 | MEN1 (0.44) | CNR1LMNATP53CNR2ESR1 | |
| SCHEMBL5216271 | 0.89 | ESR1 (0.40) | CNR1LMNATP53CNR2ESR1 | |
| SCHEMBL5217977 | 0.88 | ESR1 (0.43) | CNR1ESR1 | |
| SCHEMBL5217431 | 0.84 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5214707 | 0.84 | ESR1 (0.43) | LMNATP53ESR1 | |
| SCHEMBL5215784 | 0.83 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL5217463 | 0.83 | ESR1 (0.46) | LMNATP53ESR1 | |
| SCHEMBL5220782 | 0.82 | ESR1 (0.52) | CNR1LMNATP53CNR2ESR1 | |
| SCHEMBL5217969 | 0.82 | MAPT (0.43) | LMNATP53ESR1 | |
| SCHEMBL5218326 | 0.82 | KMT2A (0.39) | LMNATP53ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39708-E1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CNR1 160/4885LMNA 3842/4885TP53 575/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | CNR1 160/4885LMNA 3842/4885TP53 575/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CNR1 160/4885LMNA 3842/4885TP53 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.